EL7.AI
StocksMedium•16 November 2026•
4 min read

Tentative Agreement Halts States’ Lawsuit Against Teva Over Prices of More Than 100 Drugs

Key Facts

1The court paused the states’ lawsuit after a tentative agreement with Teva whose terms were not disclosed.
2The three complaints included allegations involving more than 100 generic drugs, according to New York’s attorney general.
3Teva shares closed at $44.5 on November 13, 2026.
4The trial was scheduled for February 2027 before the tentative agreement was announced.

Teva reached a tentative agreement to settle a lawsuit brought by U.S. states over allegations of fixing generic drug prices, and the court paused the case, Reuters reported on November 16, 2026. The terms of the agreement were not disclosed, so its value and financial impact on the company remain undetermined. The development is a step in a case involving allegations that drug companies coordinated to undermine competition, but it does not establish that the settlement is final. Nor does pausing this lawsuit mean that other price-related disputes involving Teva or other companies have ended. The move is significant for the company because it shifts the case toward settlement after the trial had remained on the court’s 2027 calendar.

The lawsuit concerns allegations involving more than one company and one drug. New York’s attorney general said the second complaint, filed in 2019, named Teva and 19 other major generic drug manufacturers in the United States. The three complaints, according to her description, include allegations of price fixing, avoiding competition and bid rigging involving more than 100 generic drugs. These are allegations in civil lawsuits, not a court ruling that the companies committed wrongdoing. In its quarterly filing, Teva said the states were seeking judgments under federal antitrust laws and state consumer protection and antitrust laws, as well as damages, injunctions and costs. This means the claims were not limited to monetary damages, but also included requests concerning legal liability and court-ordered measures.

The legal process had reached an advanced stage before the tentative agreement was announced. Teva disclosed that fact discovery in the three lawsuits was completed during 2025, the stage at which parties to a case gather relevant information and evidence. The trial was scheduled to begin in February 2027, according to the company’s quarterly filing. Before the agreement, a federal judge on August 20, 2026, rejected a request by defendant companies, including Teva, to reduce potential damages, Bloomberg Law reported. The rejection shows that the case was still moving through litigation in the months before the current development. The court has now paused the case following the tentative agreement, while the terms of the states’ settlement and details of its implementation have not been announced.

Teva’s agreement comes amid a broader dispute over generic drugs, in which other companies have reached settlements with the states’ coalition. On October 1, 2026, New York announced that it had joined a coalition of 47 other attorneys general to secure $400 million from Sandoz and Fougera Pharmaceuticals. The state described that settlement as the latest in a series of multistate lawsuits. It said companies that had previously settled their cases would cooperate with the coalition in lawsuits that remain ongoing. The settlement places Teva’s case in the context of a multilateral dispute spanning numerous companies and drugs, while the information made public has not disclosed the value of Teva’s agreement or whether it includes similar cooperation arrangements.

The states’ lawsuit should be distinguished from an earlier criminal case in which Teva USA admitted to antitrust violations. The company said in its filing that it admitted to agreements with competitors in 3 instances between 2013 and 2015, involving the drugs pravastatin, clotrimazole and tobramycin. Those events concern a separate matter from the tentative agreement announced in connection with the states’ lawsuit. The scope of the new settlement also does not clarify whether it will affect other lawsuits or claims by different parties against the company. Disclosures show that legal disputes involving generic drugs are not confined to one case; therefore, pausing the current lawsuit is not enough to conclude that all of the company’s legal risks have been eliminated.

Teva shares closed at $44.5 on November 13, 2026, according to EL7 data. That price is for a session before the tentative agreement was announced on November 16, and does not reflect trading after the news. The available evidence did not provide a reliable trading range for that session, so the price context is limited to the recorded close. Without the agreement’s terms, it is not possible to determine the company’s potential financial obligation or measure the settlement’s impact on its results. The next clear development will be clarification of the agreement’s terms and procedures, while the trial date in February 2027 was the announced schedule before the agreement.

Open on chart